A Single-Dose Study Evaluating the Oral Bioavailability and Pharmacokinetics of the Capsule Formulation of ABT-263 in Subjects With Cancer
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Navitoclax (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
Most Recent Events
- 06 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.